Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Somatostatin Receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Somatostatin Receptor. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-005129-35 Sponsor Protocol Number: FENET-2016 Start Date*: 2018-02-22
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: "Peptide Receptor Radionuclide Therapy (PRRT) with somatostatin analogs in tumors over-expressing somatostatin receptors"
    Medical condition: Tumors over-expressing somatostatin receptors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10014712 Endocrine neoplasms malignant and unspecified NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006889-29 Sponsor Protocol Number: MEC-2008-322 Start Date*: 2009-02-25
    Sponsor Name:ErasmusMC
    Full Title: A pilotstudy comparing systemic versus locoregional injection of radiolabelled somatostatin analogues in patients with neuroendocrine Gastro-Entero_Pancreatic (GEP) tumors.
    Medical condition: Uptake of Octreoscan in sst-2 receptor positive Gastro Entero Pancreatic neuroendocrine tumors injected in systemical and locoregional way.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001562-15 Sponsor Protocol Number: CAAA601A22301 Start Date*: 2019-11-15
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, d...
    Medical condition: Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002960-42 Sponsor Protocol Number: Yttrium-90-02 Start Date*: 2017-11-15
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA
    Full Title: 173/5000 Forse cercavi: Terapia radiometabolica recettoriale-mediata con [90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) nei tumori endocrini del tratto gastroenteropancreatico e bronchiale. (Yttrium-90...
    Medical condition: Patients with Somatostatin receptors Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014713 Endocrine neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005545-20 Sponsor Protocol Number: IJBNMDOCASTOR Start Date*: 2014-12-23
    Sponsor Name:Institut Jules Bordet
    Full Title: The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b
    Medical condition: Progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002230-20 Sponsor Protocol Number: CRN00808-03 Start Date*: 2018-11-13
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: An open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens (ACROBAT EDGE)
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) DE (Completed) GR (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004091-35 Sponsor Protocol Number: EMC-NET1 Start Date*: 2019-04-19
    Sponsor Name:Erasmus University Medical Center
    Full Title: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
    Medical condition: Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078174 Neuroendocrine tumour of the lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000549-15 Sponsor Protocol Number: S63678 Start Date*: 2020-08-05
    Sponsor Name:University Hospitals Leuven
    Full Title: Al18F-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors
    Medical condition: Neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005546-63 Sponsor Protocol Number: DOTATER1_26_15 Start Date*: 2016-05-30
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA
    Full Title: Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors.
    Medical condition: Cancer patients with high expression of somatostatin receptors (neurendocrine tumors, thyroid tumors, lung tumors, meningiomas).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000849-40 Sponsor Protocol Number: HS-19-657 Start Date*: 2021-08-23
    Sponsor Name:Camurus AB
    Full Title: A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patie...
    Medical condition: gastroenteropancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) HU (Ongoing) DE (Ongoing) NL (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005049-11 Sponsor Protocol Number: AAA-III-01 Start Date*: 2012-04-25
    Sponsor Name:Advanced Accelerator Applications
    Full Title: A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperabl...
    Medical condition: Patients with inoperable, progressive, OctreoScan® positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours), who are treated with 20 mg or 30 mg Octreotide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062392 Carcinoid tumor of the small bowel LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) PT (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002951-39 Sponsor Protocol Number: CAAA601A32201 Start Date*: Information not available in EudraCT
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheoc...
    Medical condition: somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073860 Paraganglioma LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Ongoing) PT (Ongoing) PL (Ongoing) BE (Completed) IT (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001468-12 Sponsor Protocol Number: PEN-221-001 Start Date*: 2017-01-16
    Sponsor Name:Tarveda Therapeutics, Inc.
    Full Title: A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing ad...
    Medical condition: Somatostatin receptor 2 (SSTR2) expressing advanced cancers, including gastroenteropancreatic (GEP) cancer or lung cancer or thymus cancer or other NETs (Neuroendocrine tumour) or small cell lung c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-001108-35 Sponsor Protocol Number: NRA 6290010 Start Date*: 2006-07-03
    Sponsor Name:Clinic of University of Wuerzburg
    Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY
    Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061835 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012260-14 Sponsor Protocol Number: 20050418 Start Date*: 2010-08-27
    Sponsor Name:Department of Endocrine Oncology
    Full Title: An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors
    Medical condition: Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005431-70 Sponsor Protocol Number: CRN00808-09 Start Date*: 2022-03-04
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) AT (Completed) DE (Completed) HU (Ongoing) PL (Ongoing) BG (Ongoing) ES (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004377-99 Sponsor Protocol Number: CSMS995ADE17-RNOP-11/B-01 Start Date*: 2007-04-17
    Sponsor Name:Medizinische Einrichtungen des Bezirks Oberpfalz GmbH
    Full Title: Phase I study of Somatostatin-Analogues as Second Line Treatment in Adult Patients with Recurrent Medulloblastoma (WHO IV)
    Medical condition: patients with medulloblastoma in whom therapy for primary disease (minimum: best possible resection, radiotherapy and one chemotherapy regimen) failed
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003167-38 Sponsor Protocol Number: NL50643.09r.r4 Start Date*: 2015-04-28
    Sponsor Name:Radboudumc
    Full Title: 68Ga-NODAGA-exendin-4 PET/CT in patients with AHH - a prospective comparative evaluation of preoperative imaging Under the FP7 project Betacure (602812); Personalized diagnosis and treatment of hy...
    Medical condition: Adult endogenous hyperinsulinemic hypoglycemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-006068-99 Sponsor Protocol Number: DuoNen2020 Start Date*: 2021-09-20
    Sponsor Name:Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM
    Full Title: Tandem therapy LutaPol/ItraPol (177Lu / 90Y-DOTATATE) as an effective method in the treatment of neuroendocrine neoplasms, Acronym: DuoNen, 2019 / ABM / 01/00077
    Medical condition: Diagnosed and confirmed histopathologically disseminated or locally unresectable, well and moderately differentiated (G1 and G2) neuroendocrine neoplasms of the gastrointestinal tract (GEP-NET)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001897-13 Sponsor Protocol Number: ITM-LET-01 Start Date*: 2017-08-22
    Sponsor Name:ITM Solucin GmbH
    Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar...
    Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) PL (Ongoing) CZ (Ongoing) BE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA